Distant metastasis of malignant neoplasm to the oral soft tissue is extremely rare. We report a case of renal cell carcinoma (RCC) metastasizing to the tongue. A 47-year-old man visited our hospital with chief complaint of a lump on the middle third of the dorsum of his tongue, and the lesion fell off from the tongue. Although histopathological diagnosis of the mass was granuloma teleangiecaticum, similar nodule reappeared in the same area 2 weeks later. The second lesion was composed of granuloma teleangiectaticum and aggregation of neoplastic clear cells in ductal arrangement. The clear cells were immunohistochemically positive for EMA and CD10.
Introduction
Renal cell carcinoma (RCC) is the third most frequent neoplasm to metastasize to the head and neck area, following breast and lung carcinomas [1] . The nose and paranasal sinuses are most commonly affected, followed by the oral cavity. RCC metastatic lesions to the tongue are extremely rare [2] . In the present study, we describe a case of renal cell carcinoma metastasis to the tongue, which was the first evidence of a primary tumor in the left kidney.
Case presentation
A 47-year-old male patient was referred to the Department of Oral and Maxillofacial Surgery, Nagasaki University Hospital, Nagasaki, Japan, because of a lump on the middle third of the dorsum of his tongue. The patient had been aware of the lump for approximately 2 months before visiting our hospital, and the lesion fell off from the tongue on the morning at the first visiting us. A clinical intraoral examination showed a reddish smooth lesion measuring approximately 5 x 5 mm on the anterior dorsum of the tongue (Fig. 1 ). The lump that had fallen off was lightly red in color and was an elastic, soft, and smooth mass (Fig. 2) . The patient had no history of malignant disease, drinking alcohol, or smoking. The clinical diagnosis included pyogenic granuloma and a benign tumor of the tongue. At the initial visit, the dropped lump was submitted for pathological examination. A microscopic examination revealed dilated blood vessels lined with plump endothelial cells and neutrophil infiltration under an ulcerated surface (Figs. 3) . A diagnosis of granuloma teleangiectaticum was made. Two weeks later, a similar nodule reappeared on the same part of the tongue (Fig. 4) Therefore, the patient was treated with targeted therapy by Sunitinib and by Sorafenib later. The patient was followed for 2 years after the radical nephrectomy and local exicision of the tongue, and had no evidence of recurrence in either the abdomen or tongue.
Discussion
Metastatic tumors to the tongue are extremely rare. Zegarelli et al. reported an incidence of 0.2% of 6,881 autopsy cases of various malignant diseases [2] . In addition,
Friedlander reported that only 1% of all malignancies arising in the oral cavity are metastatic foci and of these, only 5% appear on the tongue [6] .
RCC represents 3% of all adult malignancies, and it is the third most frequent neoplasm to metastasize to the head and neck region, following breast and lung carcinoma [1]. Sgouras reported the most common sites of metastasis were the lung (76%), regional lymph nodes (66%), bone (42%), and liver (41%) [7] . Approximately 15% of all patients affected with RCC have metastasis in the head and neck region.have metastasis in the head and neck region, usually associated with lesions in other sites [8] .
In the order of metastatic rate in the head and neck region, RCC affects the paranasal sinuses, larynx, jaws, temporal bone, thyroid gland, and parotid gland. However, metastatic RCCs to the tongue are extremely rare.
We reviewed 29 cases of RCC metastasizing to tongue since 1973, including the present case (Table 1) . In most cases, the lesions appeared after detection of the primary tumor, but 5 cases appeared as an initial presentation of RCC (Table 2) .
Possible routes of the metastasis to the tongue include the systemic, venous, and lymphatic circulation [9] . Most metastasis are located on the base of the tongue, most likely due to its rich vascular supply (the dorsal lingual artery), or to the immobility of this area compared with other areas of the tongue [10] . RCCs invade the local vascular network of the kidney and spread through the systemic circulation. If there are no signs of pulmonary disease, metastatic spread can be explained through Batson's venous plexus or via the thoracic duct [11] . Batson's venous plexus extends from the skull to the sacrum. This valveless system offers little resistance to the spread of tumor emboli, especially during Valsalva maneuvers when there is an increase of intra-abdominal pressure, allowing the bypass of the pulmonary filters [12] .
The treatment of RCC metastasizing to the oral cavity usually includes local excision to provide palliation of the symptom and to give patient comfort. A surgical excision has been performed to control pain and prevent bleeding and infection [13] .
Marioni et al. indicated that radiotherapy is questionable as a primary treatment [14] .
On the other hand, Azam et al. and Simo et al. have suggested the effectiveness of radiotherapy in the treatment of metastatic disease to achieve local control and for palliative management [11, 15] . Chemotherapeutic agents such as vinblastine have been proved ineffective in the treatment of advanced RCC, with a response rate lower than 10%. Cytokine-based immunotherapy (interleukin-2 and interferon-α) were the only therapeutic option for advanced RCC patients several years ago. Shibayama et al.
reported a complete response in a base of the tongue metastasis after interferon-α therapy [16] . However, the effect of this treatment is generally less than 20% [17] .
Recently target therapies are dramatically changing the landscape of advanced kidney cancer. Newer agents such as sunitinib and sorafenib, which are multiple tyrosine kinase inhibitors with proven antiangiogenic activity, have been approved for the treatment of RCCs. In the present case, the primary site was completely excised and the patient was administered adjuvant immunotherapy with interferon-α. However the patient's treatment was changed to targeted therapy with sunitinib and sorafenib because of progressive disease. Will et al. reported that most patients die within 1 year after the detection of head and neck metastasis [18] . Campbell et al. reported the overall 5-and 10-year survival rates of patients with metastatic RCC are 5-30% and 0-5%, respectively [19] . Therefore, treatments that reduce morbidity and secure comfort are essential to improve the poor long-term prognoses. 
